9
article
FasterCures Quarterly Update: July 2022
It has been a busy year so far for the FasterCures team as we advance programs to lower unnecessary
barriers to progress and accelerate biomedical innovations to all patients.
+ Read More
article
FasterCures Quarterly Update—July 2024
In This Newsletter
Highlights from Global Conference
Recent Publications
Policy Updates
FasterCures
Program Updates
+ Read More
landing page
ToolKit: Foundation’s Role in Supporting Translational Science (TRAIN)
Patient-driven foundations have been playing an increasingly active and important role in supporting
translational research from preclinical development to clinical implementation., Tools You Can Use
Related Resources:
Translating Translation, Christopher P. Austin, Nature Reviews Drug Discovery, July 2018
+ Read More
video
Advances in Science: Nothing About Us Without Us! Community Engagement in Research - Lessons from HIV and COVID-19
Hosted by Dr. Robert Eisinger, NIH, with guest speaker Judith Auerbach, PhD, Professor of Medicine
, University of California, San Francisco.
+ Read More
video
Exploring the Power of Patient Registries to Generate Real World Data and Insights
Data from and about patients is essential to advance biomedical research and development, but its
collection and dissemination can be a significant investment of time and resources for patient organizations that choose to be the intermediary.
+ Read More
article
TRAIN Newsletter — July 2024
TRAIN eNews is delivered directly to organizations that take part in The Research Acceleration and I
nnovation Network (TRAIN).
+ Read More
article
An Update from MI Health—July 2024
In This Issue:
article
Center for Public Health Newsletter: Summer 2022
Executive Director’s Note,
It’s been a busy few months since our inaugural newsletter!
article
Milken Institute Statement on Newly Released FDA Guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Trials
The Milken Institute celebrates the publication of the second iteration of the Food and Drug Adminis
tration (FDA) draft guidance on Diversity Action Plans (DAP) to improve clinical trial diversity by enrolling underrepresented populations in the US.
+ Read More